https://www.youtube.com/watch?v=qsNNUEx5OkU&t=0s
A fairly recent video where Aubrey de Grey talks about the future of regenerative medicine and how we will treat age related diseases.
Dr. Aubrey de Grey of the SENS Research Foundation gives a lecture and answers questions in Spain, April 2016.
Telomerase, an enzyme naturally found in the human organism, is the closest of all known substances to a “cellular elixir of youth.” In a recent study published in The New England Journal of Medicine, Brazilian and US researchers show that sex hormones can stimulate production of this enzyme.
The strategy was tested in patients with genetic diseases associated with mutations in the gene that codes for telomerase, such as aplastic anemia and pulmonary fibrosis.
A new story with lots of transhumanism in it:
Zoltan Istvan is in the running for President of the United States. You may not have heard of him, but if elected, he hopes to put an end to death. All of it. (Yes, seriously).
There are people right now walking around with artificial hearts – something that many people believed would not happen for another decade (or even longer). There are quadriplegics no longer bound to a wheelchair, but walk with exoskeleton technology. There are hundreds of thousands of people with brain implants that help them with various ailments. In short, recent technological breakthroughs like these open up the possibility for humans to enhance themselves and their health—and perhaps to even become immortal (someday).
Continue reading “The U.S. Presidential Candidate Who Loves Science, Technology, And…Immortality?” »
NANOG. I just like the sound of it.
In the biology lab-based equivalent of Indiana Jones and the Last Crusade, researchers from the University at Buffalo have uncovered the human body’s internal fountain of eternal youth, in the form of a gene called NANOG. When expressing this gene in aged stem cells, the team found that it reactivated certain processes that had become exhausted, restoring their ability to develop into fully functioning muscle cells.
As we go about our lives, wear and tear causes the body’s cells to die via a process called senescence. When this occurs, new cells are created from stem cells in order to replace those that have become senescent, although when we hit old age our stem cells become depleted or unable to develop.
Continue reading “There’s A Gene That Reverses Cellular Aging, And Now We Know How” »
Sure, chatbots are useful for service industries like hospitality and food delivery, but in health care? Some groups are testing the use of chatbots to retrieve medical information from within a messaging app. At first glance, that seems a bit impersonal, but a closer look reveals a wide range of use cases where bots could make your next visit to the hospital, doctor’s office, or pharmacy faster and more effective.
Let’s run this back a bit. If you’re not familiar with bots, here’s a brief explanation. Bots are software applications that run automated tasks or scripts that serve as shortcuts for completing a certain job, but they do it faster (a lot faster) and with verve. And in health care, we spend a lot of time spent generating and retrieving information.
By putting a trained army of bots inside an application — smartphone, desktop, whatever-top — health care workers can rapidly improve throughput by simply cutting out a bunch of steps. That’s something most care providers today would welcome, especially with millions of new people entering the system as a result of the Affordable Care Act and the aging of baby boomers. With the crush of increased data entry and new regulations, costs and rote work are skyrocketing.
Continue reading “How the most connected hospitals will use chatbots” »
https://www.youtube.com/watch?v=yiRf5NClQ8A
Website: http://sensproject21.org/
Building the bridge to human clinical trials for rejuvenation biotechnologies.
Awesome! Just imagine all the benefits that we will see through this research. Not only will we figure out more on the root cause of gene mutations, and cures including CRISPR; but also we will be more effective in mimicking the human system in synthetic systems, synthetic cell or gene circuitry, humanoids, synthetic immune systems, combat aging more effectively, etc.
With more data, a pioneer of gene sequencing hopes to unlock the connections between DNA and illness.
MOUNTAIN VIEW, Calif. — July 11, 2016 — SENS Research Foundation today announced its Project|21 campaign to secure $50 million in private support from individual donors, foundations, and corporations. The goal of Project|21 is for SRF to partner with a new generation of visionary philanthropists, build the Rejuvenation Biotechnology industry, and bridge the most challenging gulf between research and treatment by enabling human clinical trials by 2021.
Aubrey de Grey, founder and chief science officer of SENS Research Foundation said, “Ending aging will require large-scale investment to flow into a globally-recognized industry for rejuvenation biotechnology. Since we began in 2009, SENS Research Foundation has been putting all the pieces in place — core research groups, key players, shared knowledge, underlying tools — for the creation of this industry. The key programs funded by Project|21 can create an environment where the first damage repair interventions addressing specific age-related diseases will be brought to human clinical trials within five years.”
The programs funded under Project|21 focus on three major barriers to the development of truly effective rejuvenation therapies. First, funding to convert promising basic research programs into solid investment candidates remains far too scarce. Second, there are too few opportunities for dynamic collaborations with mainstream regenerative medicine. Finally, there is little understanding of the regulatory pathways and clinical infrastructure these technologies will require. Project|21 addresses these three areas by creating a $15 million bridge fund to support promising early stage technologies; a center of excellence to deliver better opportunities for collaborative development of early stage programs; and a Rejuvenation Biotechnology Alliance Program to address challenges in regulation, manufacturing, and investment.
